Cellectis (CLLS)

• Market cap: $311M
• 1 day: 0%
• 5 days: 2.32%
• 1 month: -21.97%
• 3 months: -7.21%
• 6 months: -33.97%
• Year to date: -35.63%
• 1 year: 125.55%
• 5 years: -80.44%
• 10 years: -89.31%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 229